The renal care sector in Gujarat is growing quickly because of the rising cases of chronic kidney disease, where the technology is also getting better, and where the India dialysis market is growing at a rate of about 9% per year through 2033. Organisational players are growing quickly because of the rise in Gujarat's healthcare infrastructure and the 13.6% CAGR in treatments for end-stage renal disease. Gujarat Kidney & Super Speciality runs seven multispeciality hospitals with 490 beds. The Gujarat Kidney IPO opening on December 22, 2025, is a great opportunity for investors who want to get in on healthcare growth.
Gujarat Kidney IPO Details:
Issue Management:
Nirbhay Capital Services Pvt. Ltd. serves as the sole book-running lead manager for the Gujarat Kidney & Super Speciality IPO, handling underwriting, regulatory compliance, and investor coordination.
Registrar Details:
MUFG Intime India Pvt. Ltd. (formerly Link Intime India Pvt. Ltd.) acts as the registrar, managing allotment status, refunds, and demat transfers – contact them at gujaratkidney.ipo@in.mpms.mufg.com or +91 810 811 4949.
Allotment Status for Gujarat Kidney IPO:
To check your IPO allotment status:
Visit the MUFG Intime India Pvt. Ltd. IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Note: 50% of shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.
Action Links:
Open Demat Account: Get started with demat here
Subscription Update: Check live subscriptions here
GMP Update: Check current grey market premiums here
The company was founded in 2019 and later changed its name to better reflect its growing clinical scope. Its main goal is to provide integrated secondary and tertiary care. The promoters mentioned above are all strong medical professionals who contribute managerial expertise to the organisation.
The company now owns seven hospitals and four pharmacies in Vadodara, Godhra, Bharuch, Borsad, and Anand. Its network has a total of 490 beds, with 445 approved and 340 operational beds. Services include inpatient and outpatient care, diagnostics, surgery, and critical care, as well as pharmacy operations inside the hospital. Its business model combines owned and acquired facilities, which makes it easy to grow and add new units quickly. The company is ready to meet the growing healthcare needs in Gujarat's semi-urban and urban markets because it has a larger regional footprint and offers speciality-driven services and technology adoption.
The Gujarat Kidney IPO Company wants to use the money it makes from the sale of shares for the following purposes:
Minimal balance covers general corporate purposes amid Gujarat's healthcare surge.
Gujarat Kidney & Super Speciality IPO's anchor book opens December 19, 2025, ahead of the main bidding – offering early institutional commitment signals for retail investors.
No specific anchor investors have been allocated shares yet, as the anchor round is scheduled one day before public subscription begins.
Likely Participants: SBI, ICICI Pru, HDFC, Axis, Nippon, Aditya Birla, and Bandhan MFs are all likely to be heavily involved, just like they were in recent healthcare IPOs like Yatharth or GPT Healthcare. Strong anchor uptake (aiming for 30–40% of the QIB quota) would confirm the 138 Cr valuation at P/E 25x FY25 earnings and raise subscription multiples. Weak interest signals caution because Gujarat is focused on its own region rather than the whole country.
The important risks and strengths of the Gujarat Kidney IPO are mentioned below:
Strengths
They are leaders in renal sciences and have strong urology subspecialties for specialised care that is in high demand.
The asset-light model focused on central Gujarat and got good returns on capital from hospitals that were the right size.
A proven track record of attracting, training, and keeping skilled medical professionals.
Facilities that are accredited and run by experienced professionals who are dedicated to operational excellence.
A steady history of making money, growing, and putting money into infrastructure for affordable care.
Risks
Acquisitions of companies that are related to promoters can lead to conflicts and problems with execution.
Adding more hospitals makes operations more complicated and makes it harder to integrate them.
Heavy reliance on the expertise of promoters makes it easier for things to change and for people to focus.
Some facilities lack interventional cardiology, limiting the company's ability to offer a comprehensive range of super-speciality services.
Gujarat Kidney & Super Speciality is a focused renal care provider in central Gujarat. It runs seven hospitals with 490 beds and is seeing strong growth in the sector. Investors may evaluate regional focus, execution on growth plans, and peer multiples against FY25 ROE 37% amid healthcare tailwinds.
As of December 10, 2025, the Gujarat Kidney IPO GMP has not been disclosed. You can view the IPO's live GMP and the subscription status. Click on the Apply Now button to proceed.
Action Links:
Open Demat Account: Get started with demat here
Subscription Update: Check live subscription here
GMP Update: Check current grey market premium here
1. What is the IPO timeline?
The anchor round opens December 19, 2025; public bidding is December 22-24; allotment is December 26; and listing is December 30 on BSE/NSE.
For the latest details, you can also look for the GMP updates.
2. What is the price band and lot size?
The price range is ₹108–114 per share, with the smallest lot consisting of 128 shares, which represents a 35% retail quota and requires a minimum investment of approximately ₹14,000.
3. What are the key financials?
FY25 revenue ₹40.4 Cr (637% YoY growth), PAT ₹9.5 Cr (454% growth), EBITDA margin 41%, ROE 37%, debt-equity 0.15.
4. How will proceeds be used?
₹138 Cr fresh issue funds Parekhs Hospital acquisition (₹77 Cr), Vadodara capex (₹30 Cr), robotics (₹6.8 Cr), debt repayment, and more.
5. Who are the main shareholders and promoters?
Dr Pragnesh Bharpoda (Chairman & MD) leads; family promoters hold 99.1% pre-IPO, diluting to ~72% post-issue.
6. What are listed peers?
Yatharth Hospital (P/E 55x), GPT Healthcare (24x), KMC Speciality (52x); GMP ₹15-18 suggests 23-27% premium
7. Who is in charge of the issue and the registrar?
Nirbhay Capital is the lead manager, and MUFG Intime (gujaratkidney.ipo@in.mpms.mufg.com) is the registrar.
